Telix Pharmaceuticals shares plunge on operational expenditure update
Make us a preferred source
Make us a preferred source on Google
More news: Telix Pharmaceuticals’ share price dropped in morning trade after the company flagged that its operational expenditure for the first half of 2025 is expected to be 36% of revenue, according to unaudited figures.
Telix shares had slipped 14.7% to $17.26 at 10:29am AEST and are down 27.7% over the year to date.
Telix Pharmaceuticals says first-half operational expenditure to be 36% of revenue
The news: Telix Pharmaceuticals says it expects to report operating expenditure for the first half of 2025 that is 36% of the period’s revenue, according to unaudited figures that were not made publicly available.
The biopharmaceutical also recast reporting for the full-year and half-year for financial years 2023 and 2024 because it has shifted to reporting in US dollars to reflect the primary denomination of its revenue, costs and cashflow.
The context: Telix told the market that its US operations have “significantly” expanded following several acquisitions including RLS Radiopharmacies, which was completed on 27 January 2025.
The operational expenditure figure, which does not include research and development spend, reflects “expanded business activities and the Company’s ongoing strategy to reinvest earnings in commercial growth and pipeline development opportunities”.
The source: ASX
